| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cryoglobulinemia | 11 | 2019 | 144 | 3.78 | Why? |
| Behcet Syndrome | 7 | 2018 | 136 | 3.30 | Why? |
| Vasculitis | 10 | 2019 | 691 | 2.47 | Why? |
| Uveitis | 10 | 2020 | 233 | 2.31 | Why? |
| Hepatitis C, Chronic | 7 | 2019 | 973 | 1.74 | Why? |
| Hepatitis C | 8 | 2018 | 1514 | 1.48 | Why? |
| Takayasu Arteritis | 5 | 2018 | 83 | 1.33 | Why? |
| Systemic Vasculitis | 2 | 2017 | 74 | 1.28 | Why? |
| Hepacivirus | 7 | 2019 | 1509 | 1.12 | Why? |
| Sarcoidosis | 5 | 2021 | 271 | 1.09 | Why? |
| Imidazoles | 3 | 2018 | 631 | 1.01 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.93 | Why? |
| Scleritis | 3 | 2020 | 25 | 0.92 | Why? |
| Infliximab | 4 | 2018 | 502 | 0.91 | Why? |
| Tuberculosis, Ocular | 2 | 2018 | 14 | 0.89 | Why? |
| Aortitis | 2 | 2017 | 39 | 0.86 | Why? |
| Diagnostic Techniques, Ophthalmological | 6 | 2018 | 136 | 0.83 | Why? |
| Adalimumab | 3 | 2018 | 389 | 0.81 | Why? |
| Sustained Virologic Response | 3 | 2018 | 378 | 0.80 | Why? |
| Rheumatoid Factor | 1 | 2019 | 67 | 0.78 | Why? |
| Anti-Glomerular Basement Membrane Disease | 1 | 2019 | 31 | 0.78 | Why? |
| Toll-Like Receptor 9 | 1 | 2019 | 72 | 0.78 | Why? |
| Immunosuppressive Agents | 15 | 2020 | 6331 | 0.76 | Why? |
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 78 | 0.71 | Why? |
| Optic Nerve Diseases | 1 | 2018 | 40 | 0.71 | Why? |
| Sclera | 1 | 2017 | 31 | 0.69 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2018 | 698 | 0.69 | Why? |
| Hepatitis Viruses | 1 | 2017 | 38 | 0.67 | Why? |
| Myocytes, Smooth Muscle | 1 | 2018 | 127 | 0.67 | Why? |
| Cryoglobulins | 1 | 2017 | 51 | 0.67 | Why? |
| Simeprevir | 1 | 2017 | 62 | 0.66 | Why? |
| Giant Cell Arteritis | 4 | 2020 | 137 | 0.66 | Why? |
| Th1 Cells | 2 | 2019 | 1228 | 0.61 | Why? |
| Immune Tolerance | 3 | 2018 | 608 | 0.61 | Why? |
| Interferon-gamma Release Tests | 2 | 2017 | 253 | 0.60 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.60 | Why? |
| Ustekinumab | 1 | 2017 | 216 | 0.58 | Why? |
| B-Lymphocyte Subsets | 1 | 2017 | 372 | 0.58 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.55 | Why? |
| Antiviral Agents | 12 | 2020 | 41703 | 0.53 | Why? |
| Autoantibodies | 4 | 2019 | 2094 | 0.52 | Why? |
| Eye Diseases | 3 | 2020 | 1150 | 0.49 | Why? |
| B-Lymphocytes | 4 | 2019 | 4418 | 0.45 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.44 | Why? |
| Receptors, Complement 3d | 3 | 2019 | 60 | 0.42 | Why? |
| Ribavirin | 2 | 2017 | 1182 | 0.42 | Why? |
| Sjogren's Syndrome | 3 | 2018 | 284 | 0.41 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.38 | Why? |
| Antirheumatic Agents | 3 | 2018 | 3023 | 0.38 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 1165 | 0.37 | Why? |
| Tumor Necrosis Factor-alpha | 5 | 2018 | 2483 | 0.36 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.34 | Why? |
| Metalloproteases | 1 | 2007 | 34 | 0.34 | Why? |
| Recurrence | 6 | 2020 | 3675 | 0.33 | Why? |
| Immunologic Memory | 1 | 2019 | 3362 | 0.33 | Why? |
| Interleukin-2 | 2 | 2018 | 443 | 0.32 | Why? |
| Remission Induction | 3 | 2018 | 950 | 0.30 | Why? |
| Aorta | 2 | 2019 | 355 | 0.30 | Why? |
| Polyneuropathies | 1 | 2007 | 157 | 0.29 | Why? |
| Valine | 2 | 2017 | 359 | 0.29 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.28 | Why? |
| Antibodies, Antiphospholipid | 2 | 2020 | 519 | 0.27 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.26 | Why? |
| Aortic Diseases | 2 | 2018 | 362 | 0.26 | Why? |
| Biological Therapy | 2 | 2018 | 456 | 0.26 | Why? |
| Treatment Outcome | 15 | 2018 | 51732 | 0.25 | Why? |
| Carbamates | 2 | 2017 | 485 | 0.25 | Why? |
| Follow-Up Studies | 10 | 2019 | 17020 | 0.25 | Why? |
| Middle Aged | 44 | 2021 | 270681 | 0.25 | Why? |
| Pyrrolidines | 2 | 2017 | 558 | 0.25 | Why? |
| Tuberculin Test | 3 | 2018 | 141 | 0.24 | Why? |
| Autoimmune Diseases | 5 | 2018 | 1996 | 0.24 | Why? |
| Th17 Cells | 2 | 2018 | 657 | 0.24 | Why? |
| Thrombosis | 3 | 2020 | 7504 | 0.23 | Why? |
| Interleukins | 2 | 2018 | 762 | 0.23 | Why? |
| Internal Medicine | 2 | 2018 | 557 | 0.23 | Why? |
| Retrospective Studies | 26 | 2021 | 105322 | 0.23 | Why? |
| Humans | 79 | 2021 | 930598 | 0.23 | Why? |
| Female | 47 | 2021 | 380317 | 0.22 | Why? |
| France | 12 | 2020 | 12074 | 0.22 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.22 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.22 | Why? |
| Rheumatic Diseases | 1 | 2017 | 2675 | 0.22 | Why? |
| Male | 43 | 2021 | 367725 | 0.21 | Why? |
| Adrenal Cortex Hormones | 4 | 2019 | 6537 | 0.21 | Why? |
| Lip | 1 | 2020 | 61 | 0.21 | Why? |
| Chemokines | 1 | 2007 | 1095 | 0.21 | Why? |
| Paris | 3 | 2021 | 1287 | 0.21 | Why? |
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2019 | 58 | 0.20 | Why? |
| Orbital Pseudotumor | 1 | 2018 | 5 | 0.20 | Why? |
| Apolipoprotein A-I | 1 | 2020 | 148 | 0.20 | Why? |
| Polymyalgia Rheumatica | 1 | 2019 | 64 | 0.19 | Why? |
| Adult | 35 | 2021 | 244371 | 0.19 | Why? |
| Cyclophosphamide | 2 | 2017 | 387 | 0.19 | Why? |
| Orbit | 1 | 2018 | 51 | 0.18 | Why? |
| Diagnosis, Differential | 6 | 2018 | 7220 | 0.18 | Why? |
| Budd-Chiari Syndrome | 1 | 2018 | 31 | 0.18 | Why? |
| Lymphoma, Primary Effusion | 1 | 2017 | 11 | 0.18 | Why? |
| Mastocytosis | 1 | 2019 | 80 | 0.18 | Why? |
| Familial Mediterranean Fever | 1 | 2019 | 88 | 0.18 | Why? |
| Tumor Necrosis Factors | 1 | 2017 | 28 | 0.18 | Why? |
| Tuberculosis, Cardiovascular | 1 | 2017 | 4 | 0.18 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.17 | Why? |
| Receptors, CXCR5 | 1 | 2017 | 35 | 0.17 | Why? |
| Intestinal Neoplasms | 1 | 2017 | 42 | 0.17 | Why? |
| Vena Cava, Inferior | 1 | 2018 | 103 | 0.17 | Why? |
| Quinoxalines | 1 | 2018 | 95 | 0.17 | Why? |
| Neuritis | 1 | 2019 | 109 | 0.17 | Why? |
| Visual Acuity | 3 | 2018 | 790 | 0.17 | Why? |
| Aneurysm, Infected | 1 | 2017 | 36 | 0.17 | Why? |
| Immunologic Factors | 3 | 2018 | 4206 | 0.17 | Why? |
| Expert Testimony | 2 | 2018 | 658 | 0.17 | Why? |
| Benzofurans | 1 | 2018 | 91 | 0.17 | Why? |
| Paraproteinemias | 1 | 2017 | 61 | 0.16 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.16 | Why? |
| Visual Fields | 1 | 2018 | 123 | 0.16 | Why? |
| Granuloma | 1 | 2017 | 88 | 0.16 | Why? |
| Lymphoproliferative Disorders | 1 | 2018 | 110 | 0.16 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2017 | 99 | 0.16 | Why? |
| Inflammation | 5 | 2020 | 13255 | 0.16 | Why? |
| Macular Edema | 1 | 2018 | 139 | 0.16 | Why? |
| Sarcoma, Kaposi | 1 | 2017 | 97 | 0.16 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.16 | Why? |
| Health Planning Guidelines | 1 | 2017 | 133 | 0.16 | Why? |
| Azathioprine | 1 | 2017 | 161 | 0.16 | Why? |
| Oral Ulcer | 1 | 2017 | 70 | 0.16 | Why? |
| Contraindications, Drug | 1 | 2017 | 281 | 0.15 | Why? |
| Still's Disease, Adult-Onset | 1 | 2017 | 100 | 0.15 | Why? |
| Drug Hypersensitivity Syndrome | 1 | 2017 | 74 | 0.15 | Why? |
| Adipose Tissue | 1 | 2021 | 612 | 0.15 | Why? |
| Aged | 25 | 2021 | 215776 | 0.15 | Why? |
| Capillary Leak Syndrome | 1 | 2017 | 119 | 0.15 | Why? |
| Oxidative Stress | 1 | 2007 | 2050 | 0.15 | Why? |
| Aneurysm, False | 1 | 2017 | 88 | 0.15 | Why? |
| Plasma Cells | 1 | 2018 | 464 | 0.15 | Why? |
| Arthralgia | 1 | 2017 | 173 | 0.15 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 350 | 0.15 | Why? |
| Urogenital Neoplasms | 1 | 2017 | 177 | 0.14 | Why? |
| Glucocorticoids | 4 | 2020 | 4431 | 0.14 | Why? |
| Rituximab | 3 | 2017 | 1096 | 0.14 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.14 | Why? |
| Aortic Aneurysm | 1 | 2017 | 121 | 0.14 | Why? |
| Autoimmunity | 2 | 2019 | 841 | 0.14 | Why? |
| Phosphorylation | 1 | 2018 | 1060 | 0.14 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.14 | Why? |
| Vision Disorders | 1 | 2018 | 260 | 0.14 | Why? |
| Prevalence | 8 | 2021 | 25773 | 0.14 | Why? |
| Time Factors | 8 | 2018 | 31397 | 0.14 | Why? |
| Pulmonary Edema | 1 | 2018 | 430 | 0.13 | Why? |
| Drug Therapy, Combination | 3 | 2017 | 7268 | 0.13 | Why? |
| Antitubercular Agents | 2 | 2017 | 775 | 0.13 | Why? |
| Plasmapheresis | 1 | 2017 | 437 | 0.13 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.13 | Why? |
| Orbital Diseases | 1 | 2018 | 339 | 0.13 | Why? |
| Pericarditis | 1 | 2019 | 417 | 0.13 | Why? |
| Patient Transfer | 1 | 2020 | 898 | 0.13 | Why? |
| Intracranial Thrombosis | 1 | 2018 | 339 | 0.13 | Why? |
| Eye | 1 | 2017 | 374 | 0.12 | Why? |
| Biological Products | 2 | 2018 | 2331 | 0.12 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Immune System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
| Kidney Failure, Chronic | 2 | 2019 | 3222 | 0.12 | Why? |
| Central Nervous System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
| Arterial Occlusive Diseases | 1 | 2017 | 363 | 0.12 | Why? |
| Signal Transduction | 2 | 2019 | 7207 | 0.11 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.11 | Why? |
| Immunoglobulins | 1 | 2017 | 811 | 0.11 | Why? |
| Pulmonary Artery | 1 | 2018 | 803 | 0.11 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.11 | Why? |
| Cells, Cultured | 2 | 2019 | 5835 | 0.11 | Why? |
| Antiphospholipid Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.11 | Why? |
| Diagnostic Imaging | 1 | 2019 | 1044 | 0.11 | Why? |
| Immunoglobulin M | 2 | 2019 | 9091 | 0.10 | Why? |
| Prognosis | 8 | 2021 | 32490 | 0.10 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.10 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.10 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.10 | Why? |
| Myocardium | 1 | 2021 | 2323 | 0.10 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.10 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2017 | 1380 | 0.09 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Folliculitis | 1 | 2008 | 12 | 0.09 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.09 | Why? |
| Staphylococcal Skin Infections | 1 | 2008 | 32 | 0.09 | Why? |
| Young Adult | 13 | 2018 | 93724 | 0.09 | Why? |
| Leukocidins | 1 | 2008 | 47 | 0.09 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.09 | Why? |
| Exotoxins | 1 | 2008 | 54 | 0.09 | Why? |
| Physicians | 2 | 2018 | 4214 | 0.09 | Why? |
| Steroids | 3 | 2020 | 904 | 0.09 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.09 | Why? |
| HSP72 Heat-Shock Proteins | 1 | 2007 | 4 | 0.09 | Why? |
| Peroneal Nerve | 1 | 2007 | 13 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.09 | Why? |
| Metallothionein | 1 | 2007 | 20 | 0.09 | Why? |
| Polyarteritis Nodosa | 1 | 2007 | 25 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Biomarkers | 4 | 2020 | 23361 | 0.08 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2007 | 87 | 0.08 | Why? |
| Bacterial Toxins | 1 | 2008 | 185 | 0.08 | Why? |
| HSP90 Heat-Shock Proteins | 1 | 2007 | 98 | 0.08 | Why? |
| Viral Load | 2 | 2017 | 15850 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Anticoagulants | 2 | 2018 | 9563 | 0.08 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.08 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.08 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.07 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.07 | Why? |
| Ophthalmology | 1 | 2020 | 1840 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.07 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.07 | Why? |
| Anti-Inflammatory Agents | 3 | 2018 | 6153 | 0.07 | Why? |
| Cardiovascular Diseases | 3 | 2019 | 11497 | 0.07 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.07 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.07 | Why? |
| Skin Neoplasms | 1 | 2017 | 1679 | 0.07 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.06 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.06 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Prednisone | 2 | 2018 | 652 | 0.06 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.06 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.06 | Why? |
| Disease Management | 2 | 2019 | 6841 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2018 | 2739 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2008 | 711 | 0.06 | Why? |
| Gene Expression Profiling | 2 | 2017 | 3788 | 0.06 | Why? |
| Neoplasms | 2 | 2021 | 17251 | 0.05 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Tissue Plasminogen Activator | 1 | 2007 | 778 | 0.05 | Why? |
| Organ Size | 1 | 2021 | 384 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Radiography, Thoracic | 1 | 2017 | 5486 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2021 | 6166 | 0.05 | Why? |
| Survival Analysis | 3 | 2018 | 7592 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Uveitis, Anterior | 1 | 2020 | 71 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Flow Cytometry | 2 | 2018 | 2393 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Up-Regulation | 1 | 2007 | 2249 | 0.05 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Biopsy | 2 | 2018 | 2811 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| B7-1 Antigen | 1 | 2017 | 39 | 0.05 | Why? |
| Registries | 1 | 2018 | 12327 | 0.05 | Why? |
| Constriction, Pathologic | 1 | 2019 | 212 | 0.05 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 7868 | 0.04 | Why? |
| Terbutaline | 1 | 2017 | 35 | 0.04 | Why? |
| Intravitreal Injections | 1 | 2020 | 347 | 0.04 | Why? |
| Retinal Vasculitis | 1 | 2017 | 33 | 0.04 | Why? |
| Theophylline | 1 | 2017 | 39 | 0.04 | Why? |
| Aortic Rupture | 1 | 2018 | 64 | 0.04 | Why? |
| Aortography | 1 | 2017 | 60 | 0.04 | Why? |
| Ophthalmologic Surgical Procedures | 1 | 2020 | 211 | 0.04 | Why? |
| Immunoprecipitation | 1 | 2018 | 300 | 0.04 | Why? |
| Age of Onset | 1 | 2019 | 557 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Stroke | 1 | 2020 | 8839 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Herpesvirus 8, Human | 1 | 2017 | 97 | 0.04 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2018 | 393 | 0.04 | Why? |
| Mesenteric Ischemia | 1 | 2018 | 128 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2018 | 21571 | 0.04 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.04 | Why? |
| Microscopy, Electron, Transmission | 1 | 2017 | 605 | 0.04 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2018 | 424 | 0.04 | Why? |
| Outpatient Clinics, Hospital | 1 | 2020 | 523 | 0.04 | Why? |
| Lymphoma, B-Cell | 1 | 2017 | 166 | 0.04 | Why? |
| Fluorescein Angiography | 1 | 2018 | 426 | 0.04 | Why? |
| Aorta, Thoracic | 1 | 2017 | 271 | 0.04 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.03 | Why? |
| Cigarette Smoking | 1 | 2018 | 337 | 0.03 | Why? |
| Medical Records | 1 | 2017 | 513 | 0.03 | Why? |
| B7-H1 Antigen | 1 | 2017 | 541 | 0.03 | Why? |
| Withholding Treatment | 1 | 2020 | 798 | 0.03 | Why? |
| Syndrome | 1 | 2018 | 1310 | 0.03 | Why? |
| Ambulatory Care | 2 | 2020 | 4947 | 0.03 | Why? |
| Adolescent | 6 | 2018 | 86841 | 0.03 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Heart | 1 | 2021 | 1791 | 0.03 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2018 | 7972 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Tomography, Optical Coherence | 1 | 2018 | 1008 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Phenindione | 1 | 2008 | 5 | 0.02 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.02 | Why? |
| Ofloxacin | 1 | 2008 | 23 | 0.02 | Why? |
| Immunomodulation | 1 | 2018 | 1472 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Groin | 1 | 2008 | 22 | 0.02 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.02 | Why? |
| Operating Rooms | 1 | 2020 | 1841 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.02 | Why? |
| Scrotum | 1 | 2008 | 48 | 0.02 | Why? |
| Leg Ulcer | 1 | 2008 | 32 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Vascular Surgical Procedures | 1 | 2017 | 882 | 0.02 | Why? |
| Stomatitis, Aphthous | 1 | 2008 | 43 | 0.02 | Why? |
| Animals | 1 | 2017 | 78931 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 170 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| Single-Cell Analysis | 1 | 2017 | 2450 | 0.02 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.02 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.02 | Why? |
| Graft Rejection | 1 | 2017 | 1766 | 0.02 | Why? |
| Computed Tomography Angiography | 1 | 2017 | 2153 | 0.02 | Why? |
| Chlorhexidine | 1 | 2008 | 176 | 0.02 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Necrosis | 1 | 2008 | 532 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Child | 3 | 2020 | 70012 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Interferon Type I | 1 | 2017 | 2789 | 0.02 | Why? |
| Interferons | 1 | 2017 | 2885 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Psoriasis | 1 | 2017 | 1739 | 0.02 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.01 | Why? |
| Anti-Infective Agents, Local | 1 | 2008 | 520 | 0.01 | Why? |
| Colchicine | 1 | 2008 | 730 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Anti-Infective Agents | 1 | 2008 | 1766 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Community-Acquired Infections | 1 | 2008 | 2328 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2008 | 10083 | 0.00 | Why? |